Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPD | P32754 | 1/20 | 0.55 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 6/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16937202 | 0.84 | OPRM1 (0.53) | TNKS2KCNH2MAOBMAOA | |
| SCHEMBL403344 | 0.78 | MAOB (0.53) | HPDMAOBMAOAGRM5 | |
| SCHEMBL6588487 | 0.78 | SPHK1 (0.55) | TNKS2KCNH2MAOBMAOAGRIN1 | |
| SCHEMBL6583023 | 0.78 | SPHK1 (0.58) | TNKS2KCNH2MAOBMAOAGRIN1 | |
| SCHEMBL9419127 | 0.78 | GRIN1 (0.48) | HPDTNKS2KCNH2MAOBMAOA | |
| SCHEMBL6583019 | 0.77 | MAOB (0.56) | TNKS2KCNH2MAOBMAOAGRIN1 | |
| SCHEMBL24461308 | 0.77 | GRIN1 (0.50) | HPDTNKS2KCNH2MAOBMAOA | |
| SCHEMBL12354455 | 0.77 | SPHK1 (0.60) | TNKS2KCNH2MAOBMAOAKDM1A | |
| SCHEMBL12971911 | 0.77 | KDM1A (0.58) | KCNH2MAOBMAOAGRIN1KDM1A | |
| SCHEMBL10352954 | 0.77 | KCNH2 (0.50) | TNKS2KCNH2MAOBSIRT1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074801-B | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclenones as antioxidant inflammatory modulators | 里亚塔医药公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-3097089-B1 | ARYL AND ARYLALKYL SUBSTITUTED PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS INC (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3097089-A1 | ARYL AND ARYLALKYL SUBSTITUTED PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | AbbVie Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9464082-B2 | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | ABBVIE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150225397-A1 | ARYL AND ARYLALKYL SUBSTITUTED PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS, INC. | 2015-08-13 | — | — | US | disclosed |
| WO-2015112792-A1 | ARYL AND ARYLALKYL SUBSTITUTED PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | ABBVIE INC. (US) | 2015-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225397-A1 | ARYL AND ARYLALKYL SUBSTITUTED PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | GPX4, TXN2, MPO | HPD 1571/4885TNKS2 2294/4885KCNH2 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.